Sofinnova Investments’s AbbVie ABBV Stock Holding History

Sofinnova Investments’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-317,783	Closed	-$72.6M	–	75
2025 Q4	$72.6M	Buy	317,783 +166,817	+110%	+$38M	3.13%	8
2025 Q3	$35M	Sell	150,966 -114,884	-43%	-$23.4M	1.91%	19
2025 Q2	$49.3M	Buy	+265,850	New	+$49.4M	3.02%	7
2025 Q1	–	Sell	-359,393	Closed	-$63.9M	–	65
2024 Q4	$63.9M	Buy	+359,393	New	+$66.1M	4.65%	4
2022 Q1	–	Sell	-312,018	Closed	-$42.2M	–	62
2021 Q4	$42.2M	Buy	312,018 +39,418	+14%	+$4.66M	2.47%	8
2021 Q3	$29.4M	Buy	+272,600	New	+$31.1M	1.74%	12
2021 Q1	–	Sell	-293,596	Closed	-$31.5M	–	65
2020 Q4	$31.5M	Sell	293,596 -47,744	-14%	-$4.59M	1.87%	13
2020 Q3	$29.9M	Buy	341,340 +89,381	+35%	+$8.41M	2.22%	10
2020 Q2	$24.7M	Buy	251,959 +201,959	+404%	+$17.8M	1.56%	16
2020 Q1	$3.81M	Buy	+50,000	New	+$4.26M	0.35%	38
2019 Q3	–	Sell	-28,911	Closed	-$2.1M	–	72
2019 Q2	$2.1M	Buy	+28,911	New	+$2.27M	0.19%	56

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sofinnova Investments's ABBV Position: Q1 2026 in Review

Sofinnova Investments sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 317,783 shares — an estimated $72.6M sold.

Sofinnova Investments first reported a position in ABBV in Q2 2019 and held it in 11 quarters. The position peaked at $72.6M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Sofinnova Investments reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Sofinnova Investments sold 317,783 AbbVie shares in Q1 2026, an estimated $72.6M.
Sofinnova Investments first reported a position in AbbVie in Q2 2019 and held it in 11 quarters.
Sofinnova Investments's AbbVie position peaked at $72.6M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.